Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl
Go back to Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl| (NASDAQ: SNDX) | Delayed: 19.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.32 | 52 Week High | $18.03 | |||
| Open | $19.32 | 52 Week Low | $8.97 | |||
| Day High | $19.32 | P/E | N/A | |||
| Day Low | $19.32 | EPS | $0.00 | |||
| Volume | 100 | |||||
